Sign up
Pharma Capital

Amryt Pharma inks exclusive Saudi Arabian distribution agreement for its Lojuxta and AP101 drugs

Under the agreement, Faisal Musaed El Seif Saudi Pharmaceutical Company will have the rights to distribute Amryt’s Lojuxta and AP101 drugs in Saudi Arabia
Riyadh city centre
This is the first licensing agreement signed since Kieran Rooney joined Amryt as Vice President of Strategic Alliances and Licensing at the end of August

AIM-listed biopharma Amryt Pharma PLC (LON:AMYT) has signed an exclusive distribution agreement with Saudi Arabian firm Faisal Musaed El Seif Saudi Pharmaceutical Company.

The deal gives El Seif the right to distribute Amryt’s Lojuxta and AP101 drugs in the kingdom.

Lojuxta and AP101

Amryt holds the exclusive marketing rights to Lojuxta last December. The drug treats a rare and life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.

It is estimated that there are more than 150 patients with HoFH in Saudi Arabia.

There is currently a lot of excitement around AP101 – the other drug covered by the agreement – which has been described as Amryt’s “lead asset”.

READ: Amryt Pharma drug exceeds expectations; potential market bigger than anticipated

Created to treat Epidermolysis Bullosa, a condition where the skin is fragile to the faintest contact, it is currently undergoing phase III clinical trials.

An interim data read-out is expected in the first half of next year. The successful completion of the full study could see AP101 fast-tracked as an orphan drug, which treats an unmet medical need.

The agreement with El Seif covers AP101 in anticipation that the treatment will successfully pass through the clinic.

Key milestone

“We are delighted to be working with El Seif and to have signed this exclusive distribution agreement which covers Lojuxta and AP101,” said chief executive Joe Wiley.

“El Seif has an extensive footprint in Saudi Arabia, and significant breadth and depth of experience and relationships across the institutional and Ministry of Health sectors.

"The signing of this partnership with El Seif is another key milestone for Amryt as we broaden our capability and reach to ensure complete coverage across our key territories."

View full AMYT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.